Pfizer secures a $10 billion deal to acquire Metsera, outbidding Novo Nordisk. The move boosts Pfizer’s presence in the fast-growing obesity drug market, signaling a major strategic comeback.

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...

Pfizer will pay $86.25 a share in cash, a premium of 3.69% to Metsera's Friday close, according to Metsera's statement. The ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

Pfizer Inc. has agreed to buy Metsera Inc. in a $10 billion deal, following a tumultuous bidding war with Novo Nordisk A/S ...

After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drug maker, Metsera decided to side with its original suitor.

Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer ...

Obesity drug developer Metsera said on Friday that it had accepted Pfizer's $10 billion acquisition offer, in what could ...

NEW YORK/LONDON (Reuters) -A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker ...

Pfizer has submitted a sweetened bid for obesity drug developer Metsera, as its fight against rival Novo Nordisk escalates, ...

Republican Chairman Ron Johnson excoriated ranking member Richard Blumenthal in a sprawling rant that transformed the hearing ...